GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Price-to-Free-Cash-Flow

Frontage Holdings (HKSE:01521) Price-to-Free-Cash-Flow : 17.75 (As of May. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Price-to-Free-Cash-Flow?

As of today (2024-05-16), Frontage Holdings's share price is HK$1.26. Frontage Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.07. Hence, Frontage Holdings's Price-to-Free-Cash-Flow Ratio for today is 17.75.

The historical rank and industry rank for Frontage Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:01521' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.57   Med: 70.74   Max: 259.5
Current: 17.75

During the past 8 years, Frontage Holdings's highest Price-to-Free-Cash-Flow Ratio was 259.50. The lowest was 17.57. And the median was 70.74.

HKSE:01521's Price-to-Free-Cash-Flow is ranked better than
70.64% of 218 companies
in the Biotechnology industry
Industry Median: 31.84 vs HKSE:01521: 17.75

Frontage Holdings's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$0.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$0.07.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Frontage Holdings was 29.60% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 4.10% per year.

During the past 8 years, Frontage Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was 64.20% per year. The lowest was -1.60% per year. And the median was 21.65% per year.


Frontage Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Frontage Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Price-to-Free-Cash-Flow Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial 221.00 69.19 - 53.70 33.14

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 53.70 - 33.14

Competitive Comparison of Frontage Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Frontage Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frontage Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frontage Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Frontage Holdings's Price-to-Free-Cash-Flow falls into.



Frontage Holdings Price-to-Free-Cash-Flow Calculation

Frontage Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.26/0.071
=17.75

Frontage Holdings's Share Price of today is HK$1.26.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Frontage Holdings  (HKSE:01521) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Frontage Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings (HKSE:01521) Business Description

Traded in Other Exchanges
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.

Frontage Holdings (HKSE:01521) Headlines

No Headlines